StreetAlpha.app
Home › Stocks › ZVRA

Zevra Therapeutics, Inc. (ZVRA)

Healthcare
$9.40
▲ +1.62%
LAST CLOSE · NOV 17

Zevra Therapeutics develops and sells treatments for rare diseases, including MIPLYFFA for Niemann Pick disease type C. It last closed at $9.40 on Nov 17, up 1.62% on the day. The average 12-month price target from 3 analysts is $19.33 (+105.7% from the last close), with a high of $21.00 and a low of $18.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ZVRA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$147.8M
+75.1% vs a year ago
Net income
$78.0M
+120.8% vs a year ago
EPS (diluted)
$1.22
+159.6% vs a year ago
Free cash flow
$38.3M
25.9% margin
Valuation
Market cap
$559.3M
59.5M shares
P/E
7.7
Price over 12 month EPS
Price to sales
3.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$122.1M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
$238.9M
Shares outstanding
59.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $28.6M$28.6MFY2021FY2022: $10.2M$10.2MFY2022FY2023: $27.5M$27.5MFY2023FY2024: $23.6M$23.6MFY2024FY2025: $106.5M$106.5MFY2025

From ZVRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ZVRA in the past 90 days
Average 12-month target
$19.33
▲ 105.7% upside

Based on 3 analysts who set a price target on ZVRA in the past 90 days. The average target is $19.33, with a high of $21.00 and a low of $18.00, compared with the last close of $9.40.

$8$13$17$22PAST 25 TRADING DAYS12-MONTH TARGETSHIGH $21AVG $19.33LOW $18Jul 24LAST CLOSE+12 MO$8$13$17$22PAST 25 DAYSTARGETSHIGH $21AVG $19.33LOW $18Jul 24LAST CLOSE+12 MO
Highest target$21.00
Average target$19.33
Lowest target$18.00
Latest rating changes
GuggenheimTarget lowered
Nov 16Buy$23 → $18
BTIGTarget lowered
Nov 13Buy$24 → $21
Cantor FitzgeraldTarget lowered
Nov 13Buy$34 → $19
GuggenheimTarget lowered
Aug 7Buy$24 → $23
CitizensMaintained
Aug 6Buy$28
DateFirmActionRatingPrice target
Nov 16GuggenheimTarget loweredBuy$23 → $18
Nov 13BTIGTarget loweredBuy$24 → $21
Nov 13Cantor FitzgeraldTarget loweredBuy$34 → $19
Aug 7GuggenheimTarget loweredBuy$24 → $23
Aug 6CitizensMaintainedBuy$28
Loading…

Technical Analysis

ZVRA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 11% below its 20 day and 16% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Jul 31) at $9.34, and the nearest resistance the Pivot R1 at $9.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 7.0%/day
Key levels
$15.0452 week high+60.0%
$11.44100 day average+21.7%
$10.8650 day average+15.5%
$10.85200 day average+15.4%
$10.55Swing high (Oct 29)+12.2%
$10.4720 day average+11.4%
$9.52Pivot R1+1.3%
$9.40Last close
$9.34Swing low (Jul 31)−0.6%
$9.29Pivot−1.2%
$9.16Pivot S1−2.6%
$8.0152 week low−14.8%
Indicators
RSI (14)39.85Weak, oversold below 30Neutral
MACD-0.18Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)21.3Weak trend
Williams %R-85.4Oversold below −80, overbought above −20Oversold
CCI (20)-121.4Oversold below −100, overbought above 100Oversold
Rate of change−8.4%Change over 10 sessionsBearish
ATR (14)$0.66Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZVRA

What happened before

See how ZVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ZVRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ZVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ZVRA in the last 90 days.

Loading…

See today’s whale options flow across the market →

ZVRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲103 buying vs 73 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding174159+9.4%
In funds' top 1021+100.0%
Held by funds80.0%78.4%+1.6 pts
New / increased41 / 6229 / 65+9.6%
Reduced / sold out48 / 2540 / 17+28.1%
Put/call ratio6.3710.72−40.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZVRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZVRA is in one of them and how their past ZVRA trades turned out.

ZVRA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZVRA in an article yet. Here's the latest on the wider market.

About Zevra Therapeutics

Zevra Therapeutics develops and sells medicines for rare diseases. Its main approved products are MIPLYFFA, an oral treatment for Niemann Pick disease type C, and OLPRUVA, used to help manage urea cycle disorders in adults and children. The company also has candidates in clinical development, including celiprolol for vascular Ehlers Danlos syndrome. Its products are sold mainly to patients and providers in the United States, and MIPLYFFA is also made available to patients in parts of Europe through an access program. The company is based in Boston, Massachusetts.

Headquarters
Boston, MA